TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02809937

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline infusion
Study: NCT06022224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD
Description: Clear and colorless liquid. Each vaccine is supplied in a 2-mL vial containing 1.0 mL of extractable vaccine at a concentration of 1 × 10\^11 viral particles/mL.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% (w/v) saline)
Description: Clear and colorless liquid.
Study: NCT02743975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-800CW
Description: dose finding: 4.5mg; 10mg; 25mg; 50mg
Study: NCT02967640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketalar
Description: 2,5 ml - if well tolerated immediately followed by another 2,5 ml - of an approximately 1 mg/ml ketalar solution (1 ml of ketalar 10 mg/ml + 9 ml of NaCl 9%) injected 2 times with 1-12 weeks between each injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketalar
Description: 2,5 ml - if well tolerated immediately followed by another 2,5 ml - of an approximately 1 mg/ml ketalar solution (1 ml of ketalar 10 mg/ml + 9 ml of NaCl 9%) injected 2 times with 1-12 weeks between each injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl 9%
Description: 2,5 ml - if well tolerated immediately followed by another 2,5 ml - of a 9% NaCl solution injected 2 times with 1-12 weeks between each injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 9%
Description: 2,5 ml - if well tolerated immediately followed by another 2,5 ml - of a 9% NaCl solution injected 2 times with 1-12 weeks between each injection
Study: NCT01780324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intervention - intraurethral lidocaine
Study: NCT03216980

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PTSD/GAD Antioxidant
Description: Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PTSD/GAD Antioxidant
Description: Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PTSD/GAD Placebo
Description: Subjects will ingest placebo (microcrystalline cellulose) pills.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PTSD/GAD Placebo
Description: Subjects will ingest placebo (microcrystalline cellulose) pills.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Healthy Control Antioxidant
Description: Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Control Antioxidant
Description: Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Healthy Control Placebo
Description: Subjects will ingest placebo (microcrystalline cellulose) pills.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Control Placebo
Description: Subjects will ingest placebo (microcrystalline cellulose) pills.
Study: NCT00357240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: Capsules, Oral, 400 mg, once daily, 6 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir/Ritonavir
Description: Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir+Omeprazole
Description: Capsules/capsules + Capsules, Oral, 300/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
Study: NCT00849186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: oral

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Surgery
Study: NCT04152187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The treatment group will receive inspiratory muscle training.
Study: NCT04579016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAIGE2 lifestyle intervention
Description: Education session during pregnancy. provision of fitness tracker, referral to commercial weight management organization, text and phone support
Study: NCT00357240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir+Omeprazole
Description: Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: Capsules, Oral, 400 mg, once daily, 6 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir/Ritonavir
Description: Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
Study: NCT04193904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRx0518
Description: MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Preoperative Radiation
Description: Radiation will be delivered as 30Gy/10 fractions over two weeks.
Study: NCT00720967

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Heart Surgery (OHS)
Description: General anesthesia, use of iodine impregnated adhesive dressing, median sternotomy and/or thoracotomy incision, full heparinization (300-400 ui/kg), arterial and venous cannulation, initialization of CPB with or without aortic cross-clamping and high-potassium cold cardioplegia, surgical repair under mild-moderate hypothermia. De-clamping (if cross clamp was applied), neutralization of heparin by protamin, de-cannulation and hemostasis after surgical repair. Insertion of drain(s) and pacing wire(s). Closure of all layers in anatomical plan.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Heart Surgery (OHS)
Description: General anesthesia, use of iodine impregnated adhesive dressing, median sternotomy and/or thoracotomy incision, full heparinization (300-400 ui/kg), arterial and venous cannulation, initialization of CPB with or without aortic cross-clamping and high-potassium cold cardioplegia, surgical repair under mild-moderate hypothermia. De-clamping (if cross clamp was applied), neutralization of heparin by protamin, de-cannulation and hemostasis after surgical repair. Insertion of drain(s) and pacing wire(s). Closure of all layers in anatomical plan.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Heart Surgery (OHS)
Description: General anesthesia, use of iodine impregnated adhesive dressing, median sternotomy and/or thoracotomy incision, full heparinization (300-400 ui/kg), arterial and venous cannulation, initialization of CPB with or without aortic cross-clamping and high-potassium cold cardioplegia, surgical repair under mild-moderate hypothermia. De-clamping (if cross clamp was applied), neutralization of heparin by protamin, de-cannulation and hemostasis after surgical repair. Insertion of drain(s) and pacing wire(s). Closure of all layers in anatomical plan.
Study: NCT00357240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir+Omeprazole
Description: Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in AM, 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir+Omeprazole
Description: Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in PM, 7 days.
Study: NCT03966872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Illness Management and Recovery
Description: Education and skills training groups on illness management of chronic medical and psychiatric illness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program
Description: Education and skills training groups on illness management of chronic conditions
Study: NCT00720967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Modified Ultrafiltration (MUF)
Description: Once the surgical repair is finished, and CPB will be stopped after aortic declamping. The arterial and venous cannulae will be connected to each other using 3-way connectors and a cardioplegia line. When hemodynamic stability is established (MAP \>75 mmHg, CVP \> 12 mmHg, Htc \> 25%), blood will be drained from the arterial cannula using a roller pump, driven to the ultrafilter, and eventually to the venous cannula. The blood flow will be maintained at \~150 mL/min, and suction will be applied to the filtrate port to achieve an ultrafiltration of 100-120 mL/min. Heat exchanger and bubble trap of the cardioplegia line will be used to maintain the filtered blood at body temperature and to prevent air embolism, respectively. MUF will continue 20 minutes. The filtered volume will be collected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Description: Two HD sessions will be performed at 3 days and 1 day prior to surgery. Each session will last 3 hours if the patient weighs \< 75 kg, and 4 hours if \> 75 kg. Conventional HD will be carried out using a volume-controlled dialysis machine. A bicarbonate dialysate containing K (3 mmol/L), Ca (1.5 mmol/L) and HCO3 (31 mmol/L) will be used. Sodium conductivity will be set at 138 mmol/L. Medium-flow filters will be used as artificial kidney devices. Dialysate temperature will be set at 36oC. Dialysate and blood flow rate will be set at 500 mL/min and 250-300 ml/min, respectively. Intradialytic ultrafiltration will not be used routinely unless the patient has volume overload. The decision to use intradialytic ultrafiltration will be taken with the anaesthesiologist and the cardiac surgeon. If intradialytic ultrafiltration is indicated, maximal rate of ultrafiltration will be 10 ml/kg/hour. These patients will undergo open heart surgery after two sessions of HD.
Study: NCT03734926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1241
Description: ZSP1241 tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1241
Description: ZSP1241 tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1241
Description: ZSP1241 tablets for oral administration.
Study: NCT03699397

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dry electrode EEG
Description: A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. To do this, the investigators will use the WaveguardTM dry electrode EEG cap and compatible eegoTM amplifier, developed by ANT Neuro B.V. Netherlands and both CE marked as medical devices in the European Union (see appendices 1 and 2). Both products will be used within the intended use as described in the user manuals. The dry electrode cap is put on the patients head and records the EEG signal for several minutes; the amplifier is used to amplify the EEG signal and reduce artefacts.
Study: NCT01832493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy
Description: All study patients were evaluated for the optimal atrial-ventricular (AV) programmed interval using various methods.
Study: NCT02158962

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral - Education
Description: Behavioral - Education~3 educational sessions aimed at reducing risks partner violence, and sexual transmitted infections
Study: NCT01536561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)
Description: 131-I anti-B1 is the product of 131-I labeling of the anti-CD20 murine monoclonal antibody and the anti-B1 antibody itself is an intact IgG2a murine monoclonal antibody which has specificity far the CD20 antigen on human B cells. Anti-B1 is a clear, colorless liquid. 131-I labeling of the anti-B1 antibody will be carried out by iodogen technique. Trace labeling of the antibody will involve the labeling of approximately 1 to 3 mg of antibody with 5 mCi of 131-I.
Study: NCT03827967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PalloV-CC
Description: The PalloV-CC vaccine uses yeast cell wall particles (YCWP) to serve as an efficient vaccine delivery system as they can contain a broad range of antigenic material, they are rapidly phagocytized by antigen presenting cells, and they are inherently immunogenic. The PalloV-CC vaccine utilizes silicate-capped YCWP to deliver allogenic colon cancer tumor lysate. The vaccine will be given to subjects with resectable colon cancers neoadjuvantly shortly before surgery in order to study the effect of the vaccine on the tumor microenvironment using a well-validated immune scoring system for colon cancer and other immunologic tests.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PalloV-CC
Description: The PalloV-CC vaccine uses yeast cell wall particles (YCWP) to serve as an efficient vaccine delivery system as they can contain a broad range of antigenic material, they are rapidly phagocytized by antigen presenting cells, and they are inherently immunogenic. The PalloV-CC vaccine utilizes silicate-capped YCWP to deliver allogenic colon cancer tumor lysate. The vaccine will be given to subjects with resectable colon cancers neoadjuvantly shortly before surgery in order to study the effect of the vaccine on the tumor microenvironment using a well-validated immune scoring system for colon cancer and other immunologic tests.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PalloV-CC
Description: The PalloV-CC vaccine uses yeast cell wall particles (YCWP) to serve as an efficient vaccine delivery system as they can contain a broad range of antigenic material, they are rapidly phagocytized by antigen presenting cells, and they are inherently immunogenic. The PalloV-CC vaccine utilizes silicate-capped YCWP to deliver allogenic colon cancer tumor lysate. The vaccine will be given to subjects with resectable colon cancers neoadjuvantly shortly before surgery in order to study the effect of the vaccine on the tumor microenvironment using a well-validated immune scoring system for colon cancer and other immunologic tests.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PalloV-CC
Description: The PalloV-CC vaccine uses yeast cell wall particles (YCWP) to serve as an efficient vaccine delivery system as they can contain a broad range of antigenic material, they are rapidly phagocytized by antigen presenting cells, and they are inherently immunogenic. The PalloV-CC vaccine utilizes silicate-capped YCWP to deliver allogenic colon cancer tumor lysate. The vaccine will be given to subjects with resectable colon cancers neoadjuvantly shortly before surgery in order to study the effect of the vaccine on the tumor microenvironment using a well-validated immune scoring system for colon cancer and other immunologic tests.
Study: NCT04579016

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Care routinely provided to all pregnant women diagnosed with GDM
Study: NCT01527812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Description: We will perform an ultrasound guided femoral nerve block. For locating the nerve a 5 cm, 6-13 MHz linear probe (Sonosite Turbo M, Bothwell WA, USA) will be used. After the examination of the anatomy of the femoral artery we will fix the probe transversal to the thigh below the inguinal crease and above the ramification of deep femoral artery and make skin marks on this position. A 22 G 50 mm long Stimuplex BBraun needle will be used. 15 ml 2 % lignocaine will be injected.
Study: NCT04258449

Intervention type: DEVICE
Intervention: DOvEEgene Fleur Sampling
Description: Patients will undergo uterine sampling with DOvEEgene Fleur endometrial sampling device prior to surgical intervention, in addition to standard of care treatment.
Study: NCT01550614

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Alferminogene tadenovec
Description: One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer)
Study: NCT04584944

Intervention type: RADIATION
Intervention: Dual energy X-ray absorptiometry
Description: Evaluation of the appendicular muscle mass of the limbs will be performed by Dual-Energy X-ray Absorptiometry, using a QDR 4500. Body composition analysis will also be evaluated with TANITA Body Composition Analyzer device,model BC-418MA. Bioelectrical Impedance Analysis measures the body composition using a constant power source (high frequency current 50kHz, 90 μA).~Muscle mass is also going to be measured by using ultrasound -U/S. It measures basic parameters such as muscle volume and spectrum length through the B-Mode imaging with Linear 7-12MHz frequency heads that can reliably determine the thickness and transverse incisions of the superficial muscular Groups.

Intervention type: RADIATION
Intervention: Dual energy X-ray absorptiometry
Description: Evaluation of the appendicular muscle mass of the limbs will be performed by Dual-Energy X-ray Absorptiometry, using a QDR 4500. Body composition analysis will also be evaluated with TANITA Body Composition Analyzer device,model BC-418MA. Bioelectrical Impedance Analysis measures the body composition using a constant power source (high frequency current 50kHz, 90 μA).~Muscle mass is also going to be measured by using ultrasound -U/S. It measures basic parameters such as muscle volume and spectrum length through the B-Mode imaging with Linear 7-12MHz frequency heads that can reliably determine the thickness and transverse incisions of the superficial muscular Groups.
Study: NCT01527812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Description: We will perform an ultrasound guided femoral nerve block. For locating the nerve a 5 cm, 6-13 MHz linear probe (Sonosite Turbo M, Bothwell WA, USA) will be used. After the examination of the anatomy of the femoral artery we will fix the probe transversal to the thigh below the inguinal crease and above the ramification of deep femoral artery and make skin marks on this position. A 22 G 50 mm long Stimuplex BBraun needle will be used. 15 ml 2 % lignocaine will be injected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Description: We will perform an ultrasound guided femoral nerve block. For locating the nerve a 5 cm, 6-13 MHz linear probe (Sonosite Turbo M, Bothwell WA, USA) will be used. After the examination of the anatomy of the femoral artery we will fix the probe transversal to the thigh below the inguinal crease and above the ramification of deep femoral artery and make skin marks on this position. A 22 G 50 mm long Stimuplex BBraun needle will be used. 15 ml 2 % lignocaine will be injected.
Study: NCT03835676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: After inclusion and baseline measurements, patients will receive treprostinil in addition to background therapy for 24 months. Follow-up assessment will include:~* Clinical, echocardiographic, laboratory assessments will be repeated at 1, 3, 6, 12, 18, and 24 month (or when there is clinical indication)~* CMR will be performed at 6 monthly intervals for 2 years.~* Peak power output at 6,12, 18 and 24 month~* Right-side cardiac catheterization will be performed at 6, 12 , 18 and 24 months (or when there is clinical indication)
Study: NCT00144781

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Description: 0.58 mg/kg every week

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Description: 1.2 mg/kg every week

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Description: 1.2 mg/kg every other week

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Description: 1.8 mg/kg every other week
Study: NCT01672216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMG-biofeedback alone
Study: NCT00587990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lower dose mesenchymal stem cell (MSC) injection
Description: Participants will receive between 10 and 20 intramyocardial injections of 2 million MSCs per 0.25-0.5 cubic centimeter (cc) for a total of 2 x 10\^7 cells. The injections will be administered following completion of CABG surgery.

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive between 10 and 20 placebo injections that consist of phosphate buffered saline (PBS) and 1% human serum albumin (HSA).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Higher dose MSC injection
Description: Participants will receive between 10 and 20 intramyocardial injections of 20 million MSCs per 0.25-0.5 cc for a total of 2 x 10\^8 cells. The injections will be administered following completion of CABG surgery.
Study: NCT01664611

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Conditioning administered via the inflation of a blood pressure cuff on the upper arm
Description: Suprasystolic blood pressure cuff inflation for set periods to time to render a limb ischaemic followed by periods of deflation to allow for reperfusion.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham conditioning
Description: Non therapeutic inflation of a blood pressure cuff that does not cause ischaemia/reperfusion injury
Study: NCT00553436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Apposition System (TAS) Device
Description: Closure of defect following polypectomy using the Tissue Apposition System (TAS) Device.
Study: NCT02896335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Administered orally once per day on days 1-21 of 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Administered orally once per day on days 1-21 of 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is administered via intravenous (IV) infusion at a dose of 200 mg over 30 minutes once every 21 days. Pembrolizumab cycles are 3 weeks (21 days) long in this study, and participants in Cohort 2 can receive pembrolizumab as long as they are receiving study drug palbociclib.